LYUMJEV KWIKPEN 300 UNIT / 3 ML
INSULIN LISPRO : 300 UNIT / 3 ML · DIN 02520206 · ELI LILLY CANADA INC
Health Canada status: APPROVED
What is LYUMJEV KWIKPEN?
LYUMJEV KWIKPEN 300 UNIT / 3 ML contains INSULIN LISPRO : 300 UNIT / 3 ML. It is listed in the Health Canada Drug Product Database under DIN 02520206, held by ELI LILLY CANADA INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 14-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02520206 |
|---|---|
| Brand name | LYUMJEV KWIKPEN |
| Generic / active ingredient | INSULIN LISPRO : 300 UNIT / 3 ML |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 300 UNIT / 3 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | A10AD04 INSULIN LISPRO |
| AHFS class | 68:20.08 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 14-Sep-2021 |
What can be used instead?
Other Canadian products sharing ATC code A10AD04 INSULIN LISPRO. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HUMALOG MIX 25 (CARTRIDGE) | 75 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02240294 |
| HUMALOG MIX 25 (KWIKPEN) | 25 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02403420 |
| HUMALOG MIX 50 (CARTRIDGE) | 50 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02240297 |
| HUMALOG MIX 50 (KWIKPEN) | 50 UNIT | SUSPENSION | ELI LILLY CANADA INC | MARKETED | DIN 02403439 |
| HUMALOG MIX 25 (PEN) | 75 UNIT | SUSPENSION | ELI LILLY CANADA INC | CANCELLED POST MARKET | DIN 02240295 |
| LYUMJEV | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520184 |
| LYUMJEV | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520192 |
| LYUMJEV JUNIOR KWIKPEN | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520214 |
| LYUMJEV KWIKPEN | 600 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520230 |
| LYUMJEV TEMPO PEN | 300 UNIT / 3 ML | SOLUTION | ELI LILLY CANADA INC | APPROVED | DIN 02520222 |
Who else supplies INSULIN LISPRO worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN LISPRO appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.